Pharmaceutical

Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio

The company has also raised $130.7m in a private placement, which along with Tectonics' previous cash reserves.

Jun 22, 2024 - 04:00
Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio
The company has also raised $130.7m in a private placement, which along with Tectonics' previous cash reserves.
Read the original article

Tags:

Previous Article

Sarepta’s Elevidys secures US label expansion for DMD

Next Article

WHO warns of “harmful” fake Ozempic in circulation in Americas and Europe

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Oft-prescribed beta blockers may not be wise for many heart patients

Oft-prescribed beta blockers may not be wise for many h...

May 3, 2023

With little FDA oversight, melatonin supplements vary widely in actual dosage, study finds

With little FDA oversight, melatonin supplements vary w...

Apr 25, 2023

Opinion: How ‘Lessons From the Covid War’ falls short

Opinion: How ‘Lessons From the Covid War’ falls short

May 17, 2023